Compare BioNano Genomics Inc (BNGO) vs Levi Strauss & Co. (LEVI) Price & Performance

Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.

BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.

Levi Strauss (LEVI) trades at $24.19, down 0.49% on the day, with a neutral technical signal and strong fundamentals. The company reported Q2 2026 EPS of $0.28, beating estimates of $0.24, and raised full-year guidance. Revenue grew 7.6% year-over-year to $1.56B, driven by direct-to-consumer strength. Valuation metrics show a P/E of 17.28 and P/S of 1.45, with robust profitability including a 61.72% gross margin and 9.66% net margin.

Outlook remains positive with 83% analyst buy ratings and a $28 consensus price target, implying 16% upside. Risks include tariff pressures and foreign exchange volatility noted in recent earnings. The dividend was increased to $0.16, supporting income investors. Continued execution on digital strategy and product expansion provides growth catalysts amid competitive apparel markets.